South Korea immunochemistry analysers market to grow at 4% CAGR through 2036, forecasts GlobalData

Driven by the rising demand for advanced diagnostics, technological advancements, and aging population, the market for immunochemistry analysers in South Korea is expected to expand at a compound annual growth rate (CAGR) of 4 per cent between 2025 and 2036, forecasts GlobalData.

GlobalData’s report, “Immunochemistry Analyzers Market Size by Segments, Share, Regulatory, Reimbursement, Installed Base and Forecast to 2036,” reveals F. Hoffmann-La Roche, Abbott Laboratories, Siemens Healthineers AG and Danaher Corp, accounted more than half of the South Korea immunochemistry analysers market in 2024.

US-based life sciences company Quanterix Corporation has received Class 1 Medical Device registration for its product HD-X Simoa Immunochemistry Analyser from South Korea’s Ministry of Food and Drug Safety (MFDS). Developed for blood-based biomarker analysis, this platform targets critical biomarkers associated with Alzheimer’s disease and other neurodegenerative conditions, enabling precise detection of both early-stage and advanced disease.

Nidhi Bharti, Medical Devices Analyst at GlobalData, comments, “The shift toward high-precision diagnostic systems is enhancing analytical capabilities, facilitating earlier detection and more accurate monitoring in vital areas such as neurology, oncology, and infectious diseases.”

The advancements in immunochemistry space are paving the way for breakthroughs in clinical research and diagnostics.

Bharti concludes, “Specifically, in the realm of neurodegenerative diseases, these enhancements are proving to be advantageous, providing a more intricate understanding of complex conditions and enhancing diagnostic accuracy. Together, these innovations are honing laboratory capabilities and revolutionising the diagnostic process across multiple medical specialties.”